Vanessa Pedrego, PA
Physician Assistant · Pomona, CANPI 1467763755
Payments from drug & device makers
Across 336 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$814
- Dexcom, Inc.$589
- Amgen$412
- Abbott$350
- Boehringer Ingelheim$336
- plus $3K from 29 others
What the payments were for
- Food & beverage$6,36899%
- Education$120%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 62 | $1,114 |
| Novo Nordisk | 44 | $814 |
| Dexcom, Inc. | 36 | $589 |
| Amgen(2 entities) | 28 | $412 |
| Abbott | 14 | $350 |
| Boehringer Ingelheim | 16 | $336 |
| Sanofi-aventis U.S. LLC | 17 | $288 |
| AstraZeneca | 12 | $235 |
| Medtronic | 14 | $232 |
| Radius Health, Inc. | 9 | $223 |
| Novartis | 10 | $212 |
| Xeris Pharmaceuticals, Inc. | 9 | $193 |
| Insulet Corporation | 9 | $172 |
| Tandem Diabetes Care, Inc. | 6 | $139 |
| Corcept Therapeutics | 5 | $115 |
| Bayer | 6 | $115 |
| Mannkind Corporation | 5 | $114 |
| Ascendis Pharma Endocrinology Inc | 3 | $83 |
| Ionis Pharmaceuticals, Inc. | 3 | $78 |
| Madrigal Pharmaceuticals | 3 | $76 |
| Amryt Pharma Holdings Ltd | 3 | $71 |
| AbbVie | 3 | $70 |
| Alvogen Inc | 3 | $65 |
| Merck | 3 | $64 |
| Pfizer | 2 | $46 |
| Averitas Pharma Inc. | 1 | $41 |
| Lifescan, Inc. | 2 | $30 |
| Chiesi USA, Inc. | 1 | $29 |
| Rhythm Pharmaceuticals, Inc. | 1 | $26 |
| Bigfoot Biomedical Inc | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| GSK | 1 | $19 |
| IBSA Pharma Inc. | 1 | $16 |
| Embecta Corp. | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,439 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 96 | $100,659 |
| TrulicityDulaglutide | 58 | $76,896 |
| JardianceEmpagliflozin | 69 | $75,892 |
| MounjaroTirzepatide | 62 | $74,082 |
| ProliaDenosumab | 39 | $64,688 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $52,614 |
| FarxigaDapagliflozin Propanediol | 69 | $51,276 |
| JanuviaSitagliptin Phosphate | 35 | $28,005 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 24 | $23,177 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $19,518 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $15,908 |
| TradjentaLinagliptin | 19 | $12,366 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $12,108 |
| Humalog Kwikpen U-100Insulin Lispro | 36 | $11,408 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 16 | $7,576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,114 | $158,109148 claims |
| Novo NordiskOzempic | $814 | $100,65996 claims |
| Boehringer IngelheimJardiance, Tradjenta | $336 | $88,25888 claims |
| AmgenProlia | $412 | $64,68839 claims |
| AstraZenecaFarxiga | $235 | $51,27669 claims |
| MerckJanuvia | $64 | $28,00535 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $288 | $23,17724 claims |
| AbbVieSynthroid, Armour Thyroid | $70 | $4,14751 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Pomona
- Natalie MarshallPomona$87K
- John QuigleyDowney$2.9M
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
- Katherine OsakiEl Centro$274K
- Shawna JonesFountain Valley$266K
- Heather AustinSalinas$219K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.